Patrizia Paterlini-Bréchot

Rarecells USA, Inc. is a company dedicated to early cancer detection to save lives. The company is based in New York, NY. The company believes that accurate and early cancer detection has the potential to save millions of lives. Rarecells is developing a prostate cancer test and a multi-cancer test for early cancer diagnosis. The company is currently conducting three clinical studies to evaluate the performance of their dedicated iset-based assay. The company was founded in 2011 by Patrizia Paterlini-Bréchot, who has been the CEO since 2011.

Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward.

Rarecells USA, Inc. is a company dedicated to early cancer detection to save lives. The company is based in New York, NY. The company believes that accurate and early cancer detection has the potential to save millions of lives. Rarecells is developing a prostate cancer test and a multi-cancer test for early cancer diagnosis. The company is currently conducting three clinical studies to evaluate the performance of their dedicated iset-based assay. The company was founded in 2011 by Patrizia Paterlini-Bréchot, who has been the CEO since 2011.

Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward.

Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward.

Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward.

Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward.